羧基端阻断sortilin结合增强额颞叶痴呆小鼠模型中的颗粒体蛋白前体基因治疗
额颞叶痴呆常由颗粒体蛋白前体(PGRN)基因功能丧失突变引起,基因治疗和减少PGRN与sortilin相互作用的药物已进入临床试验。本研究在PGRN缺陷小鼠中比较表达完整sortilin结合能力的PGRN、羧基端阻断sortilin结合的PGRN或GFP对照的基因治疗载体效果。结果显示,羧基端阻断的PGRN在注射部位和远端区域产生更高水平PGRN,更有效改善微胶质增生、脂质异常和行为异常,并降低血浆神经丝轻链水平。
要点
- 羧基端阻断sortilin结合的PGRN基因治疗在PGRN缺陷小鼠中产生更高PGRN水平。
- 该修饰更有效改善微胶质增生、微胶质脂褐素沉着和脂质异常。
- 仅羧基端阻断PGRN纠正行为异常并降低血浆神经丝轻链。
核心结论
- 修饰PGRN货物以阻断sortilin相互作用可能提高PGRN基因治疗的效果。
研究设计与样本
- 在PGRN缺陷小鼠中比较表达完整sortilin结合PGRN、羧基端阻断sortilin结合PGRN或GFP对照的基因治疗载体效果。
主要发现
- 羧基端阻断PGRN在注射部位和更远端区域产生更高水平PGRN。
- 羧基端阻断PGRN更有效改善微胶质增生、微胶质脂褐素沉着、微胶质形态改变和脂质异常包括神经节苷脂积累和bis(monoacylglycero)phosphate脂质丢失。
- 无偏机器学习分析检测的行为异常在羧基端阻断PGRN治疗后消失,而未阻断PGRN未纠正。
- 仅羧基端阻断PGRN降低PGRN缺陷小鼠血浆神经丝轻链(轴突损伤生物标志物)。
临床怎么用
- 修改PGRN货物以阻断sortilin相互作用可能增强PGRN基因治疗疗效,支持进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Frontotemporal dementia is commonly caused by loss-of-function mutations in the progranulin gene. Potential therapies for this disorder have entered clinical trials, including progranulin gene therapy and drugs that reduce progranulin interactions with sortilin. Both approaches ameliorate functional and pathological abnormalities in mouse models of progranulin insufficiency. Here, we investigated whether modifying the progranulin carboxyl terminus to block sortilin interactions would improve the efficacy of progranulin gene therapy. We compared the effects of treating progranulin-deficient mice with gene therapy vectors expressing progranulin with intact sortilin interactions, progranulin with the carboxyl terminus blocked to reduce sortilin interactions, or GFP control. We found that expressing carboxyl-terminally blocked progranulin generated higher levels of progranulin both at the injection site and in more distant regions. Carboxyl-terminally blocked progranulin was also more effective at ameliorating microgliosis, microglial lipofuscinosis, microglial morphology changes, and lipid abnormalities including ganglioside accumulation and loss of bis(monoacylglycero)phosphate lipids. Behavioral abnormalities detected in progranulin-deficient mice using an unbiased machine learning analysis were absent after treatment with carboxyl-terminally blocked progranulin but not corrected by unblocked progranulin. Last, only carboxyl-terminally blocked progranulin reduced plasma neurofilament light chain, a biomarker of axonal damage, in progranulin-deficient mice. These results demonstrate that modifying the progranulin cargo to block sortilin interactions may be important for increasing the effectiveness of progranulin gene therapy.
引用
- Kashyap SN, Fox SN, DeNittis VR, et al. Carboxyl-terminal blockade of sortilin binding enhances progranulin gene therapy in a mouse model of frontotemporal dementia. Sci Transl Med. 2026. PMID: 42616842. doi:10.1126/scitranslmed.adr9158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。